Dr. Worophong Manuskiatti has been invited to present results of his study “Treatment of striae distensae in skin phototypes IVV with a TriPollar radiofrequency device” in the upcoming meeting of the European Academy of Dermatology and Venereology (EADV) Conference held on October 710, 2009 in Berlin, Germany.

The oral presentation will take place on Thursday, October 8, 2009 at 10151145 in session FC 2 Lasertherapy, room 43.

In the clinical study, seventeen females with stretch marks underwent six weekly treatments with the apollo(TM) device Pollogens latest aesthetic solution based on TriPollar(TM) technology. Results showed that at one week after the final (sixth) treatment, 38.2% and 11.8% of the patients were assessed to have 2550% and 5175% improvement in the appearance of their stretch marks, respectively. The long term effect of the treatment was confirmed during the 6 weeks follow up which showed that a higher percentage of the patients were rated to have improvement of their stretch marks, including 26.5% and 5.9% showing 5175% and >75% improvement, respectively None of the participants were rated as having no improvement in their clinical appearance of stretch marks. Patient satisfaction was also measured and 65% of patients reported that they were very satisfied with the treatment, 23% were satisfied and 12% were slightly satisfied.

Full study results have recently been published in the online edition of the Journal of Dermatological Treatment.

Dr. Manuskiatti commented “Stretch marks are a skin condition that has been traditionally very challenging to treat. The study confirms that collagen remodeling induced by RF heating is an effective mechanism for improving the surface appearance of stretch marks. I am delighted that TriPollar(R) technology delivered significant measurable results that were maintained during the long term followup examination and that patients reported a pain free and pleasant experience”.

Company Founder and CEO, Dr. Zion Azar stated “Pollogen is delighted to have results of its study presented at the upcoming EADV congress. TriPollar offers a proven alternative to invasive treatments and it is important that dermatologists are exposed to leading technologies and solutions that they can offer their patients. A primary audience for this treatment is postpregnancy women who would like to eliminate abdominal stretch marks safely, effectively and in a completely painless and fast procedure.

About Pollogen

Pollogen Ltd. develops, manufactures and markets professional medical aesthetic devices, powered by the TriPollar(TM) 3rd generation Radio Frequency (RF) technology. Invented and perfected by Pollogen, proprietary TriPollar(TM) technology powers a full line of clinicallyproven, noninvasive and nonsurgical treatment platforms for wrinkles, cellulite, circumference reduction and skin tightening. The flagship aesthetic devices, apollo(TM) and regen(TM) offer customers clinicallyproven, safe and effective antiaging beauty treatments that deliver immediate and longlasting results

Source Pollogen Ltd

Provectus Pharmaceuticals, Inc. (OTCBBPVCT), a developmentstage oncology and dermatology biopharmaceutical company, has added Mount Sinai School of Medicine as its second and final site for its expanded Phase 2 clinical trial of the Companys lead dermatology agent PH10 for psoriasis. Jason Emer, M.D. will serve as principal investigator of the trial; he is also the lead investigator for the Phase 2 clinical trial of PH10 for atopic dermatitis, for which patient enrollment was completed in June.

Craig Dees, Ph.D., CEO of Provectus said, “Dr. Emers work with PH10 for atopic dermatitis, his involvement in the ongoing research of the product as a dermatological therapy, and Mount Sinai School of Medicines outstanding reputation in dermatological research make this center an outstanding choice for the second and final site of our ongoing Phase 2 trial for psoriasis.”

Enrollment in the Phase 2 trial for psoriasis commenced in July 2009, and has an expected enrollment of 30 subjects. It is a nonrandomized, open label, single group assignment trial that is designed to measure safety and efficacy of PH10. PH10 is an aqueous hydrogel formulation of rose bengal disodium for topical administration to the skin, and is being studied for the treatment of cutaneous skin disorders, specifically psoriasis and atopic dermatitis. The estimated primary completion date for final data collection is February 2010, with the study estimated to be completed by April 2010. Patients interested in participating in the trial may find further information at the NIH clinical trials registry, clinicaltrials.gov or at pvct.com.

Craig Dees, Ph.D., CEO of Provectus added, “The addition of this second site at Mount Sinai School of Medicine supports our developmental efforts for PH10 which include either a licensing agreement or codevelopment partnership for our dermatological treatments. We are continuing to explore these possibilities with major parties in the dermatology sector as this trial proceeds towards completion.”

According to the National Institutes of Health, as many as 7.5 million Americans, approximately 2.2 percent of the U.S. population, have psoriasis. The National Psoriasis Foundation reports that approximately 125 million people worldwide, 2 to 3 percent of the total population have psoriasis. It also reports that total direct and indirect health care costs of psoriasis for patients are approximately $11.25 billion annually.

Source

Dandruff affects the scalp and causes flakes of skin to appear it is a common condition. Our skin cells are forever renewing themselves. When the skin cells on our scalp are renewed the old ones are pushed to the surface and out of the scalp. For a person with dandruff the renewal is faster, meaning more dead skin is shed, making the dandruff more noticeable. Dandruff can also occur if the scalp is frequently exposed to extreme temperatures. Dandruff is also known as scurf its medical term is Pityriasis capitis.

The word dandruff comes from (most likely) dand (origin unknown) and E. Anglian (England) dialect huff, hurf, meaning “scab”. This is probably linked to the Old Norse word hrufa, meaning “scab”. The Old High German word hruf means “scurf”. According to Medilexicons medical dictionary, dandruff is “The presence, in varying amounts, of white or gray scales in the hair of the scalp, due to excessive or normal branny exfoliation of the epidermis.”Seborrheic dermatitisThis is a skin condition in which the skin becomes inflamed or flaky. Seborrheic dermatitis of the scalp is a severe form of dandruff. When it affects the scalp most people refer to it as dandruff. When babies have it, it is referred to as cradle cap. Seborrheic dermatitis causes larger, greasier flakes than most other types of dandruff. Seborrheic dermatitis affects not only the scalp, but the skin in other parts of the body too.What are the signs and symptoms of dandruff? There are while flakes of skin on the scalp, and in the persons hairFlakes may be oily lookingHead may feel tight and itchyHead may feel tinglyHead may feel soreRed, flaky, greasy patches of skin (adults, Seborrheic dermatitis of the scalp in adults) Crusting and scaling rash on scalp (babies with Seborrheic dermatitis, or cradle cap) Most cases of dandruff do not require a visit to the doctor. However, those who still find themselves scratching their scalp, if parts of the scalp become red or swollen, after a few weeks of selftreatment should see their doctor. The person may have severe seborrheic dermatitis or another condition that has dandruff symptoms.Click below if you have a particular interest in specialized news, news alerts, and newsfeeds.

News on Skin Conditions

News on Eczema and Psoriasis

News on Skin CancerWhat causes dandruff? The exact cause of seborrheic dermatitis is unknown. Most experts do know, though, that it is not caused by poor hygiene.Not enough hair brushing People who do not comb/brush their hair regularly have a slightly higher risk of having dandruff this is because they are not aiding the shedding of skin that combing/brushing provides.
Yeast People who are sensitive to yeast have a slightly higher risk of having dandruff, so it is logical to assume that yeast may play a part. Yeastsensitive people who get dandruff find that it gets better during the warmer months and worse during the winter. UVA light from the sun counteracts the yeast. Some say, though, that during winter the skin is drier because of cold air and overheated rooms (exposure to extreme temperatures), making dandruff more likely. So, it is sometimes not that easy to know whether it is yeast or just dry skin.
Dry skin people with dry skin tend to get dandruff more often. Winter cold air, combined with overheated rooms is a common cause of itchy, flaking skin. People with dandruff caused by dry skin tend to have small flakes of dandruff; the flakes are not oily.
Seborrheic dermatitis (irritated, oily skin) People with seborrheic dermatitis are very prone to dandruff. Seborrheic dermatitis affects many areas of the skin, including the backs of the ears, the breastbone, eyebrows, and the sides of the nose, not just the scalp. The patient will have red, greasy skin covered with flaky white or yellow scales.
Not enough shampooing some people say that if you dont shampoo enough there can be a buildup of oil and dead skin cells, causing dandruff. However, many experts doubt this is true.
Certain skin conditions People with psoriasis, eczema and some other skin disorders tend to get dandruff much more frequently than other people.
Some illnesses Adults with Parkinsons disease and some other neurological illnesses are more prone to having dandruff and seborrheic dermatitis. Patients recovering from heart attacks and strokes, and some people with weak immune systems may have dandruff more often than other people.
Reaction to hair/skin care products Some people react to some hair care products with a red, itchy, scaling scalp. Many experts say that shampooing too often may cause dandruff as it can irritate the scalp.
Malassezia Malassezia is a fungus that lives on everybodys scalp. Generally, it will cause no problems at all. However, it can grow out of control. It feeds on the oils our hair follicles secrete. When this happens the scalp can become irritated and produces extra skin cells. These extra skin cells die and fall off; they mix with the oil from the hair and scalp, and turn into what we see as dandruff.
Diet Some experts say that people who do not consume enough foods that contain zinc, B vitamins, and some types of fats are more prone to dandruff.
Mental stress Experts believe there is a link between stress and many skin problems.
HIV A study found that 10.6% of people with HIV have seborrheic dermatitis.Diagnosis of dandruffYou do not need a doctor to diagnose dandruff. You can do this yourself. If you see the characteristic white flakes on your scalp, you have dandruff.

If you still want to see a doctor, no special preparations are needed to help the doctor diagnose dandruff. Diagnosis will be confirmed by looking at the scalp and skin. Anybody who has started using some new hair care product may find it useful if they bring the bottles with them.

If your dandruff gets no better after some weeks of selftreatment, you should then consider seeing your doctor, especially if there are red, swollen patches on the scalp.What is the treatment for dandruff? Two factors should be considered when you treat dandruff 1. Your age. 2. The severity of your dandruff. Your aim will be to stop the dandruff by slowing down the reproduction of skin cells, and/or counteract the yeast production that might be the cause.

Shampoos and scalp preparations

Shampoos and products for the scalp are available OTC (overthecounter, no prescription needed) at most supermarkets, pharmacies and many corner shops. It is important to remember that seborrheic dermatitis can be controlled, but not cured with these products.

Before using an antifungal shampoo see if you can remove any scaly or crusty patches on your scalp do this with care. If you manage to remove them the shampoo will be more effective.

If you have dandruff on your beard you can use dandruff shampoo on it.

Most antidandruff or antifungal shampoos contain at least one of the following active ingredientsZinc pyrithione an ingredient which slows down the production of yeast.
Selenium sulphide this reduces the production of natural oils your scalp glands produce.
Coal tar this has a natural antifungal agent. If your hair is dyed or treated remember that longterm coal tar usage can stain the hair.
Ketoconazole a very effective antifungal. Most people who use this are pleased with the results. Experts say shampoos with this ingredient can be used with young and elderly people.
Salicylic acids these help your scalp get rid of skin cells. It does not slow down the reproduction of skin cells. Many “scalp scrubs” contain salicylic acids. Some people find salicylic acid treatments leave their scalps dry and eventually make the flaking of the skin worse.
Teatree oil This oil comes from the Australian Tea Tree (Melaleuca alternifolia). A growing number of shampoos now include teatree oil as one of its ingredients. It has been used for centuries as an antifungal, antibiotic, and an antiseptic. However, some people are allergic to it.
Green Tea potential Researchers from the Medical College of Georgia, USA, found that green tea may have potential for the treatment of dandruff and psoriasis.Ideally, select a shampoo that has one of the above ingredients and shampoo your hair with it every day until your dandruff is under control. When that happens use them less frequently. You may find a particular shampoo stops being so effective after while, if this occurs switch to one that has another ingredient.

Make sure the shampoo has time to stay on your scalp before you rinse it off perhaps about five minutes. If you rinse it off too quickly the ingredient will not have enough time to work.

If after several weeks of treating yourself you still have dandruff, you should consider seeing your doctor or a dermatologist (skin specialist).

A study carried out by European researchers suggested that the addition of llama antibodies to shampoo could be a new strategy for fighting dandruff.ComplicationsA person with dandruff or seborrheic dermatitis will hardly every experience complications. If one were to occur, it would more likely to be caused by one of the dandruff treatments. If you find one of your dandruff shampoos, or scalp treatments is causing irritation, stop using it and ask your pharmacist to suggest another one.

Bacteria can get in under your skin if there is a break on the skin of the scalp. If this happens, and you feel unwell, or that area of skin is red, tender and swollen, go and see your doctor.

CanFite BioPharma (TASECFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, has achieved yet another goal by completion of patients enrollment in its phase II Psoriasis trial. Approximately 70 patients were enrolled to this study, randomized into 4 groups treated with 1, 2 and 4 mg of CF101 and placebo. Patients are taking the drug for 12 weeks plus 2 weeks of followup. The trial is being conducted in 10 sites in Israel and Europe. The company estimates to release study data on Q3 2009.

A point to note it that similarly to the patients in the Dry Eye study, which was recently successfully concluded, the patients in the current study were also treated with CF101 as a stand alone.

Psoriasis is a skin condition that affects 2% to 3% of the general population. The disease is manifested by scaly plaques on the skin and in the severe form has a major effect on the physical and emotional wellbeing of the patients. General antiinflammatory agents such as topical corticosteroids, Methotrexate or phototherapy are only partially effective and are limited by safety issues. Recently, novel biologics targeting the underlying immunopathogenesis of the disease have been introduced, such as Enbrel, which blocks the activity of the inflammatory cytokine tumor necrosis factorα (TNFα). Still, a significant need remains for novel drugs for patients who do not respond to existing therapies or for whom these therapies are unsuitable.

The market share for Psoriasis is estimated at US$ 3.5 billion annually. The oral administration of CanFites CF101, the drugs mechanism of action (suppression of the inflammatory mediator TNFα) and its excellent safety profile (tested on more than 600 subjects in other trials), support its use for the treatment of psoriasis.

Prof. Pnina Fishman, CEO of CanFite, said today that, “We are very happy with the progress in our clinical development program and looking forward to analyze the data of this study in which CF101 was given as a monotherapy. It is our first trial in the dermatology field and the immunomodulatory activities of CF101 render it a possible attractive drug candidate for these clinical conditions.”

Source

Blacks and others with darker skin might be at greater risk for tobacco addiction than whites and those with lighter skin because the greater the amount of melanin, the coloring pigment in skin, the more nicotine appears to be stored, according to preliminary findings published in the journal Pharmacology, Biochemistry and Behavior, the New York Times reports. For the study, lead researcher Gary King, a professor of biobehavioral health at Pennsylvania State University, looked at 150 black smokers and measured their levels of melanin and cotinine, a byproduct of nicotine. They also surveyed the participants to determine the level of their smoking habit.

Those with the most melanin were found to smoke the most and have the most cotinine in their system. They also had the highest level of dependence on tobacco. The findings might indicate why some people are more affected by nicotine than others, according to the study (Nagourney, New York Times, 5/19).

An abstract of the study is available online.

Reprinted with kind permission from kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation.

© 2009 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

Skin from a factory this has long been the dream of pharmacologists, chemists and doctors. Research has an urgent need for large quantities of skin models, which can be used to determine if products such as creams and soaps, cleaning agents, medicines and adhesive bandages are compatible with skin, or if they instead will lead to irritation or allergic reactions for the consumer. Such test results are seen as more meaningful than those from animal experiments, and can even make such experiments largely superfluous.

But artificial skin is rare. “The production is complex and involves a great deal of manual work. At this time, even the markets established international companies cannot produce more than 2,000 tiny skinpieces a month. With annual requirements of more than 6.5 million units in the EU area alone, however, the industrial demand far exceeds all currently available production capacities,” reports Jörg Saxler. Together with Prof. Heike Mertsching, he is coordinating the “Automated Tissue Engineering on Demand” project within the FraunhoferGesellschaft.

Tissue engineering is still in its infancy. “Until now, the offer was limited predominantly to singlelayer skin models that consist of a single cell type,” explains Mertsching, who heads the Cell Systems Department at the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB. “Thanks to developments at our institute, the project team has access to a patentprotected skin model that consists of two layers with different cell types. This gives us an almost perfect copy of human skin, and one that provides more information than any system currently available on the market.”

An interdisciplinary team of Fraunhofer researchers is currently developing the first fully automatic production system for twolayer skin models. “Our engineers and biologists are the only ones who have succeeded in fully automating the entire process chain for manufacturing twolayer skin models,” explains Saxler, who is from the Fraunhofer Institute for Production Technology IPT where he is responsible for technology management and heads the “Life Science Engineering” business unit. In a multistage process, first small pieces of skin are sterilized. Then they are cut into small pieces, modified with specific enzymes, and isolated into two cell fractions, which are then propagated separately on cell culture surfaces. The next step in the process combines the two cell types into a twolayer model, with collagen added to the cells that are to form the flexible lower layer, or dermis. This gives the tissue natural elasticity. In a humid incubator kept at body temperature, it takes the cell fractions less than three weeks to grow together and form a finished skin model with a diameter of roughly one centimeter. The technique has already proven its use in practice, but until now it has been too expensive and complicated for mass production. Mertsching explains, “The production is associated with a great deal of manual work, and this reduces the methods efficiency.”

The project team, in which engineers, scientists and technicians from four Fraunhofer institutes are cooperating, is currently working at full speed to automate the work steps. The researchers at the IGB and the Fraunhofer Institute for Cell Therapy and Immunology IZI are handling the development of the biological fundamentals and validation of the machine and its submodules. Experts from the Fraunhofer Institute for Manufacturing and Automation IPA and the Fraunhofer Institute for Production Technology IPT are taking care of prototype development, automation and integration of the machine into a complete functional system. “At the beginning, our greatest challenge was to overcome existing barriers, because each discipline had its own very different approach,” Saxler remembers. “Meanwhile, the four institutes are working together very smoothly everyone knows that progress is impossible without input from the others.” After working together for one year, the project team has already initiated eight patent procedures.

At a collective FraunhoferGesellschaft booth at the 2009 BIO in Atlanta, the researchers are presenting a computer model of the overall system, along with the three fundamental submodules. The first module prepares the tissue samples and isolates the two cell types; the second proliferates them. The finished skin models are built up and cultivated in the third, and then packed by a robot.

The researchers still have a lot of meticulous work ahead before the machine will be finished. The difference between success and failure often depends on details, such as the quality of the skin pieces, processing times of enzymes, and liquid viscosities. Furthermore, the cell cultures must be monitored throughout the entire manufacturing process in order to provide optimal process control and to allow timely detection of any contamination with fungi or bacteria. The skin factory is expected to be finished in two years. “Our goal is a monthly production of 5,000 skin models with perfect quality, and a unit price under 34 euros. These are levels that are attractive for industry,” Saxler continues.

But chemical, cosmetic, pharmaceutical, and medical technology companies who have to test the reaction of skin to their products are not the only ones interested in Automated Tissue Engineering. In transplantation medicine, surgeons require healthy tissue in order to replace destroyed skin sections when burn injuries cover large portions of the body. The twolayer models that the new machine is intended to produce are not yet suitable for this purpose, however. “They dont have a blood supply, and are consequently rejected by the body after some time,” Saxler explains.

But IGB researchers are already working on a fullskin model that will even include blood vessels. Once the research has been completed, fully automatic production of the transplants should also be possible. “We have designed the production system in such a way that it satisfies the high standards for good manufacturing practices (GMP) for the manufacture of products used in medicine,” Mertsching explains. “And so they are also suitable for producing artificial skin for transplants.”

This release is available in German.

Source
Dr. Heike Mertsching

Cardium Therapeutics (NYSE Amex CXM) and its subsidiary Tissue Repair Company (TRC) announced significant new formulation enhancements for its Excellarate(TM) product candidate that are designed to simplify and broaden the use of Excellarate for diabetic ulcers, and also expand the potential applicability into a number of additional wound healing market opportunities, including pressure and venous stasis ulcers, as well as major surgical and serious trauma wounds.

Excellarate is a collagenbased topical gel employing TRCs Gene Activated Matrix(TM) (GAM) technology to stimulate a patients cells to produce a sustained microrelease of plateletderived growth factorB (PDGFB) protein directly within the patients wound where it is needed. PDGFB is believed to stimulate angiogenesis and granulation tissue formation through the recruitment and proliferation of cells such as monocytes, fibroblasts and endothelial cells, which are critical for the effective stimulation of a variety of wound healing processes.

On May 6, 2009, Cardium announced the completion of recruitment for the Phase 2b MATRIX clinical trial to evaluate the safety and efficacy of Excellarate for the treatment of nonhealing diabetic foot ulcers. The MATRIX Data and Safety Monitoring Board has reviewed safety data collected from study participants as of April 21, 2009 and reported that Excellarate appears to be both safe and well tolerated, with no serious adverse events attributable to the study product. Approximately 70% of the patients recruited in the MATRIX study have already completed their initial evaluation period with respect to key efficacy criteria, particularly the percentage of patients achieving complete wound closure, the rate of wound closure and the reduction of wound size at various time points. With confirmation of one or more medically meaningful responses, Cardium and TRC would expect to meet with the U.S. Food and Drug Administration (FDA) to review the complete safety and efficacy database from this Phase 2b clinical study and their plans for initiating a largerscale Phase 3 pivotal study.

New Excellarate(TM) Product Formulations for Expanded Applications

In parallel with the Phase 2b study and in anticipation of a Phase 3 clinical study and future commercialization, the Companys continuing process development activities have led to an important breakthrough in product formulation that not only significantly simplifies the use of Excellarate, but opens the door to additional potential applications of the Excellarate technology in a number of other wound healing market opportunities. The product formulation that was used in the Phase 2b study required storage in a 70 degrees Celsius freezer and a two syringe mixing process prior to treatment. The new product formulation is designed to be maintained in a physicians office using a standard refrigerator (at a temperature of about 4 degrees Celsius) and to have a shelf life of 1218 months. It will also be formulated as an easytouse single syringe that is premixed and ready to be applied to patients wounds.

With these product formulation enhancements and the accumulating data on Excellarate, Cardium is now focused on establishing additional costeffective therapeutics that carry the potential to extend well beyond the initial indication of nonhealing diabetic foot ulcers. In addition to the single syringe refrigerated formulation to facilitate storage and easeofuse, Cardium and its manufacturing partners are developing lowcost and efficient largescale production processes for DNAbased therapeutics using bioreactors with high cell densities and hightiter productivities. The relatively low dosing requirements for this new class of product candidates is enabled by TRCs GAM technology which causes the protein to be produced by a patients own cells for a sustained period of time and locally released where it is needed within the wound site. The low dosing requirements relative to proteinbased therapeutics, combined with the much lower costs of DNAbased product manufacturing, creates the potential for a new class of highly effective low cost therapeutics for application in a number of different tissue repair and wound treatment settings.

The Excellarate product candidate is initially being developed to facilitate wound closure in nonhealing diabetic foot ulcers, which affect about 15% of the 24 million diabetic patients in the United States or about 3.6 million patients. The ability to achieve closure of chronic, nonhealing wounds following application of a simple topical gel is considered to be particularly important for patient populations with chronic diseases such as diabetes. Available advanced wound care products for these patients have a number of limitations such as requiring a regimen of repeated wound cleanings and product readministrations, or multiple trips to a treatment center, or custom produced and expensive skin substitute products. In addition, many patients, including approximately one in seven participants in the MATRIX clinical study, have wounds that do not close even after treatments with what are regarded as the most advanced wound care therapies currently available (i.e., repeatadministration therapies using Becaplermin protein [Regranex(R)] or negative pressure pumps, or “livingskin” equivalents).

With the new product formulation enhancements and the accumulating data on Excellarate, this technology has the potential to be developed into additional costeffective therapeutics with expanded clinical utility. The broader fields of wound healing and tissue repair involve an order of magnitude more patients than those with diabetic ulcers, and these other fields are likewise in need of innovative products. There are a number of key market drivers behind the growth in advanced wound care products. Nonhealing or slow healing wounds in patients are highly susceptible to becoming infected, both in hospital and out. Furthermore, the use of antibiotics in these patients has resulted in the outgrowth of antibiotic resistant pathogens. Most importantly for patients and their physicians, wounds that have become infected can lead to amputations, a result that is often associated with a dramatic increase in mortality even in societies with optimal medical care. In the United States, for example, nonhealing ulcers among diabetic patients are the leading cause of amputation, and even with care approximately half of such patients die within three years of their amputation.

These emerging trends and growing market demand are evidenced by the recent success of negative pressure wound therapy products, such as those marketed and sold in the United States by Kinetics Concepts Inc. and Smith & Nephew, which represent the first $1.0 billion product segment in the wound care market. Based on these trends and needs, wound healing agents designed to accelerate the rate of wound healing are expected to play a more prominent role in the future of advanced wound care. As reported by MedTech Insight, the wound care market is projected to experience double digit growth over the next 3 to 5 years, with advanced wound care products comprising the fastest growing segment of the total wound care market. There are an estimated 91.3 million wounds in the U.S., which include 67.0 million surgical wounds, 17.6 million trauma wounds including burn injuries, amputations and traumatic wounds, 2.5 million pressure ulcers, 3.6 million diabetic ulcers and 3.3 million venous stasis and arterial ulcers. The ability to effectively address even a small proportion of these wounds would represent major new market opportunities for application of Tissue Repairs GAM technology.

About Cardium

Cardium Therapeutics, Inc. and its subsidiaries, InnerCool Therapies, Inc. and the Tissue Repair Company, are medical technology companies primarily focused on the development, manufacture and sale of innovative therapeutic products and devices for cardiovascular, ischemic and related indications.

Cardiums InnerCool Therapies subsidiary is a San Diegobased medical technology company in the emerging field of temperature modulation therapy to rapidly and controllably cool the body in order to reduce cell death and damage following acute ischemic events such as cardiac arrest or stroke, and to potentially lessen or prevent associated injuries such as adverse neurological outcomes.

Adults in Sheffield with skin complaints will soon be able to receive treatment in community settings, rather than having to travel to the hospital, thanks to NHS Sheffields planned changes to the citys dermatology services.

Specialist dermatology services are planned for three areas in Sheffield, one to cover the North of the city, one in the East/SouthEast and one in the West/ SouthWest. The services will overture patients appointments with specialists in Dermatology who can diagnose and treat skin conditions including eczema, psoriasis and skin lesions.

Healthcare professionals and organisations are currently being offered the opportunity to highlight to NHS Sheffield the organization responsible for deciding how NHS money is spent in the city why they feel they would be the unrivaled society to deliver the services.

The crowned applicants will have to meet a statistic of criteria, including demonstrating crack public transport urls to the venue, commendable parking facilities, the ability to deliver at least 15% of the services outside of the hours of 9am 5pm and the specialist facilities needed to meet infection supervision specifications. Services in the three areas may end up being run by one organisation, or by several, dependent on who will provide the champion workable dispensation for humans in Sheffield. All organisations will be recommended to provide the value to the indistinguishable unbroken and will be appropriate to cooperate with each other as well as the hospital and GPs.

In 2007, NHS Sheffield conducted a thorough consultation beyond the city commanded Achieving Balanced fine feather, the outcomes of which showed that brothers of the public overwhelmingly wanted as copious services as indeterminate close to their homes, rather than in hospital settings.

The resulting Achieving Balanced salubriousness strategy is all about driving forwards these changes, in that case bringing dermatology services out into the community (as has already unusable the case in other areas including Leeds and East Riding). GPs from Hallam and South PBC consortium with support from Clinicians from other PBC Consortia cross Sheffield have obsolescent useful with NHS Sheffield and with confined Hospital Dermatologists to redesign Skin Services in the city. As a returns NHS Sheffield undertook a further survey with dermatology patients, who said that they would allied to receive treatment in the community.

The survey showed that of highest importance to them would be locations with satisfying public transport (81% felt that was bulky or very imperative); rad parking was following (70%); and patients felt that of least importance to them was knowing the customer treating them (only 42% marked that as necessary or very foremost).

Clinical front station for Hallam and South Consortium Dr Andy Hilton said “We have worked closely with Dermatologists, Specialist nurses, GPs and patients to agree what conditions could be managed in a community shade. It has anachronistic imperative to reach that consensus to ensure a big quality employ for patients, which GPs are willing to refer into, and which Dermatologists feel offers appropriate care at a formidable definitive. With that new kindness model we feel we have achieved that”

title role for improving dermatology services at NHS Sheffield, Kate Gleave said “surrounded by 17% and 29% of Sheffield mortals suffer from dermatological disputeds particle.

“that copper will attempt a multitude of improvements to the utility these inhabitants receive, including making them closer to where human race grindstone and living, and potentially speeding up treatment its anticipated that patients will be seen and treated by the specialist in the interchangeable day.

“Were confident that well receive advances from a folio of organisations, expressing a wish to deliver that community based ministration, enabling us to pick the providers that will presentation the boss duck soup care for mortals in the city.”

It is anticipated that the community based work will be offered from Summer 2009.

The changes to the dispensation will not overcome how patients are managed within their GP surgeries, and they should ride to have a look at their GP with initial concerns about their skin. If appropriate the GP would suddenly refer them. For some conditions, patients will still be referred to the hospital.

Attendees at the American Society of Plastic Surgeons (ASPS) 2008 annual meeting in Chicago explored the latest technological innovations in patient drilling at the InfoSurge exhibition booth. InfoSurge, a convention that designs custom on the internet patient knowledge courses, presented demonstrations of its innovative product, including new 3D videos designed to educate patients about breast augmentation procedures.

Visitors to the booth commented that they appreciated the visual attractiveness of the new tutelage videos out the use of explicit graphics and icons that can intimidate thinkable patients. Computer demonstrations of the InfoSurge patient proselytism logical order highlighted the philosophys ease of use, its ability to liberate surgical practices duration and money on educating patients, and tools for achieving overall improvements in practice management by delivering consistent educational messages while documenting all patient participation and comprehension.

Eran Kabakov, InfoSurge CEO, said, “The turnout for that years ASPS meeting exceeded our expectations. We have participated in ASPS meetings for three years, but that was the first year that Ive seen such a enormous response beginning with the opening day. Our goals were to gain new surgeon clients and foster new strategic networks; I am very happy with the results. We received manifold inquiries about our on the internet patient learning arrangement, and a few surgeons signed with us on the spot. I thank our numberless visitors for making that years meeting a winning event for us.”

Larry Goldsmith, VP of livelihood Development for InfoSurge, said, “I was very appealsed that various young, aspiring surgeons were particularly interested in learning more about our on the internet patient scholarship setup. The discussions we had with them demonstrated to us that our technology is completely in tune with what young plastic surgeons expectations and plans are for developing their future practices.”

The InfoSurge on the net patient civilization orderliness serves the requirements of plastic and aesthetic surgeons by providing the ideal solution to the following patient coaching challenges

Patients confusion about medical jargon
Risk of frivolous litigation
accrual moment demands on staff
Difficulty of achieving thorough informed consent
goconsuming literacy seminars
Managing patients expectations.

For more material or to chat breathing with an on the internet representative, please browse the InfoSurge valid website, infosurge.com, or whoop 18882030465.

About InfoSurge

InfoSurge, founded by healthcare professionals in 2005, produces custom on the net patient drilling modules that provide physicians with solutions to the daily challenges of extent constraints, malpractice risks, summing competition, and unrealistic patient expectations. InfoSurges on the web direction systems combine the benefits of elearning software with the advantages of patientfriendly medical courses.

Attendees at the American Society of Plastic Surgeons (ASPS) 2008 annual meeting in Chicago explored the latest technological innovations in patient literacy at the InfoSurge exhibition booth. InfoSurge, a cortege that designs custom on the internet patient erudition courses, presented demonstrations of its innovative product, including new 3D videos designed to educate patients about breast augmentation procedures.

Visitors to the booth commented that they appreciated the visual attractiveness of the new drilling videos outofdoors the use of explicit graphics and similitudes that can intimidate unrealized patients. Computer demonstrations of the InfoSurge patient tuition orderliness highlighted the classifications ease of use, its ability to recover surgical practices eternity and money on educating patients, and tools for achieving overall improvements in practice management by delivering consistent educational messages while documenting all patient participation and comprehension.

Eran Kabakov, InfoSurge CEO, said, “The turnout for that years ASPS meeting exceeded our expectations. We have participated in ASPS meetings for three years, but that was the first year that Ive seen such a fat response beginning with the opening day. Our goals were to gain new surgeon clients and foster new strategic associations; I am very happy with the results. We received lousy with inquiries about our on the web patient drilling scheme, and a few surgeons signed with us on the spot. I thank our bountiful visitors for making that years meeting a winning event for us.”

Larry Goldsmith, VP of livelihood Development for InfoSurge, said, “I was very orisonsed that umpteen young, aspiring surgeons were particularly interested in learning more about our on the web patient rearing complex. The discussions we had with them demonstrated to us that our technology is completely in tune with what young plastic surgeons expectations and plans are for developing their future practices.”

The InfoSurge on the web patient cultivation red tape serves the requirements of plastic and aesthetic surgeons by providing the ideal solution to the following patient learning challenges

Patients confusion about medical jargon
Risk of frivolous litigation
computing generation demands on staff
Difficulty of achieving thorough informed consent
boutconsuming training seminars
Managing patients expectations.

For more lore or to chat breathing with an on the net representative, please explore the InfoSurge proper website, infosurge.com, or job 18882030465.

About InfoSurge

InfoSurge, founded by healthcare professionals in 2005, produces custom on the web patient tuition modules that provide physicians with solutions to the daily challenges of ticks constraints, malpractice risks, accretion competition, and unrealistic patient expectations. InfoSurges on the web indoctrination systems combine the benefits of elearning software with the advantages of patientfriendly medical courses.